Search results
13 hours ago · Following the latest results, Verve Therapeutics' ten analysts are now forecasting revenues of US$20.6m in 2024. This would be a sizeable 28% improvement in revenue compared to the last 12 months.
Title Album details Peak chart positions US US R&B; Soulsinger: Released: January 1, 2000; Label: LeSun Records; Formats: CD — — Feeling Orange but Sometimes Blue
5 days ago · The Loop, Rakei’s fifth album, marks his recent signing to Verve Forecast and Decca UK. Recorded at RAK Studios, the album was self-produced by Rakei and mixed by Ben Baptie (Moses Sumney,...
5 days ago · Tags: music, news, music-news, tour, new-music, singersongwriter, jordan rakei, decca records, verve forecast, uk. New Zealand-born and London-based songwriter, producer and GRAMMY Award-nominated multi-instrumentalist Jordan Rakei has confirmed additional tour dates in the United States and Canada. Rakei is touring in support of his album The ...
4 days ago · Analyst Forecast According to 6 analysts, the average rating for VERV stock is "Buy." The 12-month stock price forecast is $35.33, which is an increase of 451.17% from the latest price.
2 days ago · Buy Rating Affirmed for Verve Therapeutics Amid Progress and Promising Pipeline. May 8, 2024 | msn.com. Verve Therapeutics GAAP EPS of -$0.59 beats by $0.12, revenue of $5.7M beats by $3.45M. May 8, 2024 | investorplace.com. VERV Stock Earnings: Verve Therapeutics Beats EPS, Beats Revenue for Q1 2024.
4 days ago · VERVE-102 is designed to turn off the PCSK9 gene with a goal of durably lowering LDL-C in patients living with either HeFH or premature CAD, and we look forward to evaluating the safety and ...
